The Patent Finder

Sumitomo Pharma Co., Ltd.

137 patents currently held · Updated Nov 21, 2026
57 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as Sumitomo Dainippon Pharma Co., Ltd. (to 2022)

10
Ending by 2030
May 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for 1,4-disubstituted imidazole derivative (US 11,661,397) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 2 fees due Dec 9 to 18, 2026 · next Dec 9
  • 3 fees due Jan 2 to 18, 2027 · next Jan 2
  • 5 fees due Feb 8 to 28, 2027 · next Feb 8
  • 3 fees due Mar 1 to 12, 2027 · next Mar 1
  • 4 fees due Apr 10 to 24, 2027 · next Apr 10
  • 1 fee due Jun 5, 2027
    The maintenance fee for Vaccine adjuvant formulation (US 11,833,247) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
  • 4 fees due Aug 16 to 27, 2027 · next Aug 16
  • 3 fees due Sep 12 to 24, 2027 · next Sep 12
  • 5 fees due Oct 12 to 28, 2027 · next Oct 12

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026
  • 3 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,980,316Stable Tablet Containing Droxidopa
In force
 · High confidence
In forceHigh confidence
US 8,710,057Imidazo[1,2-b]pyridazine and Pyrazolo[1,5-a]pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 7,750,007Imidazo[1,2-beta]pyridazine and PYRAZOLO[1,5-Alpha]PYRIMIDINE Derivatives and Their Use as Protein Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,067,4139-Substituted-8-OXO-ADENINE Compounds as Toll-Like Receptor (TLR7 ) Modulators
In force
 · High confidence
In forceHigh confidence
US 7,906,510Amide Derivative and Pharmaceutical Composition Containing the Same
In force
 · High confidence
In forceHigh confidence
US 8,178,102Emulsified Composition for Dilution and Cancer Vaccine Composition
In force
 · High confidence
In forceHigh confidence
US 8,471,038Novel Bicyclic Heterocyclic Compound
In force
 · High confidence
In forceHigh confidence
US 9,533,978Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases
In force
 · Medium confidence
In forceMedium confidence
US 8,598,370Process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine
In force
 · USPTO record
In forceUSPTO record
US 8,933,2298-Azabicyclo[3.2.1]OCTANE-8-Carboxamide Derivative
In force
 · High confidence
In forceHigh confidence
10 of 137 patents shown.
Pro members see all 137.
Pro members: see all 137 patents
Also on record, not counted in the 137: 57 patents in force now held by others · 17 lapsed for an unpaid fee · 22 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

53 pending · 17 abandoned · 23 no status recorded

Showing 1 to 10 of 93, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/281,992Nitrogen-Containing Saturated Heterocyclyl DerivativeJul 28, 2025Pending
19/090,175Cell Population for Transplantation and Method for Producing SameMar 25, 2025Pending
19/059,437Ulotaront Hydrochloride Manufacturing ProcessFeb 21, 2025Pending
19/053,477Methods of Administering Neuropsychiatric Medications Based on Renal ImpairmentFeb 14, 2025Pending
19/047,358Tertiary Amide Derivatives Substituted with 4-MEMBERED Ring StructureFeb 6, 2025Pending
19/044,665Optically Active Azabicyclo Ring DerivativeFeb 4, 2025Pending
19/024,072Jan 16, 2025No status recorded
19/013,028Jan 8, 2025Pending
18/987,706Dec 19, 2024Pending
18/954,799Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with CancerNov 21, 2024Pending
10 of 93 applications shown.
Pro members see all 93 published applications.
Pro members: see all 93 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited